SynGen Inc. Hires Former Becton, Dickinson and Company (BDX) Business Development Manager As President Of Cell Processing Business Unit

SACRAMENTO, Calif., Nov. 30, 2014 /PRNewswire/ -- SynGen Inc., a company that focuses on the development and commercialization of instrument systems that harvest stem and progenitor cells from umbilical cord blood, bone marrow, peripheral blood, and cell culture, announced today that it has appointed David Hodl, formerly Business Development Manager for Becton Dickinson, to lead commercialization efforts for the newly formed Cell Processing Business Unit.

David brings 19 years of experience in product commercialization and business development in the life science and medical products industry. During his tenure with BD's Corporate Innovation Center, he led the commercialization of several cell-based technologies, including BD FACS CAP, an antibody-based cell surface marker profiling platform and BD's Discovery Platform, a custom cell culture environment development service. He also played a leading role in executing the development partnership between BD and Fate Therapeutics to access proprietary technology for developing products for expansion and differentiation of induced pluripotent stem cells.

"We are very excited about bringing David on board," said William Gerber, SynGen's President and Chief Executive Officer.  "David's experience, reputation, skills and insight are exactly what we need as we continue to grow our product lines, and move into the Cell Processing Market."

About SynGen's Cell Processing Instrumentation Product Line:

SynGenX-Lab System:  The SynGenX-Lab System is designed for the efficient extraction of target cell populations from bone marrow or blood samples in a closed, sterile device, and was designed for use in cell processing laboratories.  The system provides flexibility in the processing of high-value cells and enables cell harvesting, cell washing, volume reduction/concentration, and cell separation without Ficoll.  The SynGenX-Lab provides high recovery rates and viability of target cell populations.
SynGen CellWashPRO:  The SynGen CellWashPRO system is a new product that enables further automation of the cell washing process, with recoveries of over 90% after multiple wash cycles, with minimal loss of cell viability.  Integrated temperature and mass sensors provide process data for cGMP-compliant records.  This system will be ready for beta testing at select sites in the spring of 2015.
About SynGen Inc.

SynGen advances regenerative medicine and other emerging applications for high-value cells by providing researchers, clinicians and manufacturers with innovative, robust systems that improve the recovery, purity and viability of stem and other clinically significant cells from umbilical cord blood, peripheral blood, bone marrow and cell culture.

For more information about SynGen, visit the company's website at www.syngeninc.com.

Company Contact:

Lee Asplund, Director of Sales and Marketing

Phone: 916-706-0923   Email: [email protected]

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/syngen-inc-hires-former-becton-dickinson-business-development-manager-as-president-of-cell-processing-business-unit-300001465.html

SOURCE SynGen Inc.

Sponsored by GenScript

Accelerate Biologics, Gene and Cell Therapy Product Development partnering with GenScript ProBio

GenScript ProBio is the bio-pharmaceutical CDMO segment of the world’s leading biotech company GenScript, proactively providing end-to-end service from drug discovery to commercialization with professional solutions and efficient processes to accelerate drug development for customers.

Suggested Articles

While the biotech IPO market booms, it can look like going public is easy. But the right strategy, syndicate and aftermarket are still important.

Gene therapy pioneer Jim Wilson and the University of Pennsylvania are teaming up with Regeneron to help deliver its COVID antibody intransally.

Forty percent of PK deficiency patients on mitapivat had hemoglobalin responses, compared to 0% in the placebo group.